CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-in-the-management-of-acute-ischemic-stroketia/18133/

This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/preventing-ischemic-stroke-in-todays-world/18130/

This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/the-frontier-of-stroke-diagnosis-rapidai-how-can-artificial-intelligence-improve-acute-care-for-ischemic-and-hemorrhagic-stroke/18129/

Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-in-the-management-of-intracranial-hemorrhage-in-the-anticoagulated-patient/18128/

Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/abc-ich-does-care-bundling-improve-outcomes-for-patients-with-intracranial-hemorrhage/18127/

Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/while-antiplatelets-are-goodthey-arent-for-everyone/18131/

This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/the-path-forward-whats-on-the-horizon/18132/

This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/providing-optimal-care-for-the-anticoagulated-patient-with-intracranial-hemorrhage-in-the-acute-care-setting-does-the-patient-need-reversal-repletion-or-surgery/18125/

Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.

CME credits: 1.50

Valid until: 27-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/implementation-of-the-2022-ahaasa-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhageare-you-doing-enough/18126/

Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.

CME credits: 0.25

Valid until: 26-02-2025

Claim your CME credit at https://reachmd.com/programs/cme/case-based-management-of-hyperkalemia-to-optimize-raasi-therapy-in-patients-with-ckd/16624/

Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.

=